

Acromegaly - Pipeline Review, H2 2020

<https://marketpublishers.com/r/A501AB72FA4EN.html>

Date: September 2020

Pages: 96

Price: US\$ 2,000.00 (Single User License)

ID: A501AB72FA4EN

Abstracts

Acromegaly - Pipeline Review, H2 2020

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Acromegaly - Pipeline Review, H2 2020, provides an overview of the Acromegaly (Hormonal Disorders) pipeline landscape.

Acromegaly is a hormonal disorder that develops when pituitary gland produces too much growth hormone during adulthood. Symptoms include body odor, easy fatigue, headache, large feet, excessive height, swelling of the bony areas around a joint, widely spaced teeth and sleep apnea. Treatment includes surgery, dopamine agonists and growth hormone antagonists.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Acromegaly - Pipeline Review, H2 2020, provides comprehensive information on the therapeutics under development for Acromegaly (Hormonal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Acromegaly (Hormonal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Acromegaly and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 2, 7, 4, 4, 3 and 1 respectively.

Acromegaly (Hormonal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note:

Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Acromegaly (Hormonal Disorders).

The pipeline guide reviews pipeline therapeutics for Acromegaly (Hormonal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Acromegaly (Hormonal Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Acromegaly (Hormonal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Acromegaly (Hormonal Disorders)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Acromegaly (Hormonal Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Acromegaly (Hormonal Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Global Markets Direct Report Coverage

Acromegaly - Overview

Acromegaly - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Acromegaly - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Acromegaly - Companies Involved in Therapeutics Development

Antisense Therapeutics Ltd

Aquestive Therapeutics Inc

Ascil Projectos SL

Auritec Pharmaceuticals Inc

Camurus AB

Chiasma Inc

Crinetics Pharmaceuticals Inc

Daewoong Pharmaceutical Co Ltd

Dauntless Pharmaceuticals Inc

DexTech Medical AB

Enesi Pharma Ltd

Foresee Pharmaceuticals Co Ltd

GeneScience Pharmaceuticals Co Ltd

GlyTech Inc

Ionis Pharmaceuticals Inc

Italfarmaco SpA

OPKO Health Inc

Pharmathen Global BV

Strongbridge Biopharma plc

Acromegaly - Drug Profiles

atesidorsen sodium - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

DP-2018 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

FP-002 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IONIS-GHRLRx - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ITF-2984 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Ianreotide SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MOD-12014 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

octreotide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

octreotide acetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

octreotide acetate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

octreotide acetate CR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

octreotide acetate DR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

octreotide acetate microspheres - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

octreotide LA - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

octreotide LA - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

octreotide SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

paltusotine - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Somadex - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptides to Agonize Somatostatin Receptors for Acromegaly - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

veldoreotide ER - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

veldoreotide IR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Acromegaly - Dormant Projects

Acromegaly - Discontinued Products

Acromegaly - Product Development Milestones

Featured News & Press Releases

Sep 04, 2020: Crinetics Pharmaceuticals provides new data from Paltusotine and ACTH antagonist development programs at European Congress of Endocrinology

Aug 31, 2020: Chiasma announces U.S. commercial launch and availability of MYCAPSSA, the first and only oral somatostatin analog for patients with acromegaly

Aug 17, 2020: Chiasma announces publication of pivotal data from the phase 3 CHIASMA OPTIMAL clinical trial in the journal of Clinical Endocrinology & Metabolism

Jul 27, 2020: Chiasma announces 48-week safety and efficacy data from the open-label extension study of its CHIASMA OPTIMAL phase 3 trial evaluating MYCAPSSA in patients with acromegaly

Jul 08, 2020: Crinetics Pharmaceuticals receives orphan drug designation for Paltusotine for the treatment of acromegaly

Jul 02, 2020: Camargo client Chiasma receives FDA approval for first and only oral somatostatin analog for long-term maintenance treatment of acromegaly

Jun 26, 2020: Chiasma announces FDA approval of MYCAPSSA (Octreotide) capsules, the first and only oral somatostatin analog

Jun 11, 2020: Crinetics Pharmaceuticals confirms completion for half of the enrolled patients in the ongoing phase 2 ACROBAT edge clinical trial for Paltusotine

Apr 06, 2020: Crinetics Pharmaceuticals reports positive interim results for the ACROBAT Edge phase 2 trial of Paltusotine (CRN00808) in acromegaly patients and provides corporate update

Jan 13, 2020: Chiasma announces FDA acceptance of MYCAPSSA New Drug Application Resubmission

Aug 26, 2019: Acromegaly early access program - status update

Jul 23, 2019: Chiasma announces positive phase 3 top-line results from CHIASMA OPTIMAL clinical trial of Mycapssa for the maintenance treatment of adults with Acromegaly

Jun 27, 2019: Chiasma provides update on ongoing Mycapssa phase 3 clinical trials

Jun 20, 2019: Camurus Receives IND Acceptance From the FDA to Enter Phase 3 with CAM2029 for Treatment of Acromegaly

Jun 05, 2019: Chiasma strengthens leadership team ahead of anticipated commercial availability of Mycapssa

Appendix

Methodology

Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Acromegaly, H2 2020
Number of Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020
Products under Development by Companies, H2 2020 (Contd..1), H2 2020
Number of Products by Stage and Target, H2 2020
Number of Products by Stage and Mechanism of Action, H2 2020
Number of Products by Stage and Route of Administration, H2 2020
Number of Products by Stage and Molecule Type, H2 2020
Acromegaly - Pipeline by Antisense Therapeutics Ltd, H2 2020
Acromegaly - Pipeline by Aquestive Therapeutics Inc, H2 2020
Acromegaly - Pipeline by Ascil Proyectos SL, H2 2020
Acromegaly - Pipeline by Auritec Pharmaceuticals Inc, H2 2020
Acromegaly - Pipeline by Camurus AB, H2 2020
Acromegaly - Pipeline by Chiasma Inc, H2 2020
Acromegaly - Pipeline by Crinetics Pharmaceuticals Inc, H2 2020
Acromegaly - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2020
Acromegaly - Pipeline by Dauntless Pharmaceuticals Inc, H2 2020
Acromegaly - Pipeline by DexTech Medical AB, H2 2020
Acromegaly - Pipeline by Enesi Pharma Ltd, H2 2020
Acromegaly - Pipeline by Foresee Pharmaceuticals Co Ltd, H2 2020
Acromegaly - Pipeline by GeneScience Pharmaceuticals Co Ltd, H2 2020
Acromegaly - Pipeline by GlyTech Inc, H2 2020
Acromegaly - Pipeline by Ionis Pharmaceuticals Inc, H2 2020
Acromegaly - Pipeline by Italfarmaco SpA, H2 2020
Acromegaly - Pipeline by OPKO Health Inc, H2 2020
Acromegaly - Pipeline by Pharmathen Global BV, H2 2020
Acromegaly - Pipeline by Strongbridge Biopharma plc, H2 2020
Acromegaly - Dormant Projects, H2 2020
Acromegaly - Discontinued Products, H2 2020

List Of Figures

LIST OF FIGURES

Number of Products under Development for Acromegaly, H2 2020
Number of Products under Development by Companies, H2 2020
Number of Products by Targets, H2 2020
Number of Products by Stage and Targets, H2 2020
Number of Products by Mechanism of Actions, H2 2020
Number of Products by Stage and Mechanism of Actions, H2 2020
Number of Products by Routes of Administration, H2 2020
Number of Products by Stage and Routes of Administration, H2 2020
Number of Products by Molecule Types, H2 2020
Number of Products by Stage and Molecule Types, H2 2020

COMPANIES MENTIONED

Antisense Therapeutics Ltd
Aquestive Therapeutics Inc
Ascil Proyectos SL
Auritec Pharmaceuticals Inc
Camurus AB
Chiasma Inc
Crinetics Pharmaceuticals Inc
Daewoong Pharmaceutical Co Ltd
Dauntless Pharmaceuticals Inc
DexTech Medical AB
Enesi Pharma Ltd
Foresee Pharmaceuticals Co Ltd
GeneScience Pharmaceuticals Co Ltd
GlyTech Inc
Ionis Pharmaceuticals Inc
Italfarmaco SpA
OPKO Health Inc
Pharmathen Global BV
Strongbridge Biopharma plc

I would like to order

Product name: Acromegaly - Pipeline Review, H2 2020

Product link: <https://marketpublishers.com/r/A501AB72FA4EN.html>

Price: US\$ 2,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/A501AB72FA4EN.html>